Hanmi Reports 2026 Second Quarter Results

On July 21, 2026 Hanmi Financial Corporation (NASDAQ: HAFC, or "Hanmi"), the parent company of Hanmi Bank (the "Bank"), reported financial results for the second quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Net income for the second quarter of 2026 was $23.5 million, or $0.79 per diluted share, compared with $22.6 million, or $0.75 per diluted share for the first quarter of 2026. The return on average assets for the second quarter was 1.20% and the return on average equity was 11.09%, compared with a return on average assets of 1.18% and a return on average equity of 10.86% for the first quarter of 2026.

CEO Commentary
"Hanmi delivered another quarter of strong earnings growth, reflecting consistent execution across our business," said Bonnie Lee, President and Chief Executive Officer. "Our capital position remained healthy while returning 58% of earnings to shareholders in the form of dividends and share repurchases. Return on average equity increased to 11.1%, supported by robust deposit growth, solid loan production, lower funding costs, and prudent expense management. Deposits grew 2.3% sequentially, with noninterest-bearing deposits increasing 5.2%, underscoring the strength of our relationship-based banking model and the value of our franchise."

"Consistent with our strategy, we maintained a steady pace of loan production while continuing to diversify our loan portfolio. Importantly, credit quality remained excellent, reflecting our prudent underwriting standards and disciplined approach to risk management."

"Based on our strong first-half performance, robust loan and deposit pipelines, and the momentum we are seeing across the business, we remain optimistic about our outlook and are confident in our ability to deliver continued earnings growth and strong financial performance through the second half of 2026," concluded Lee.

Second Quarter 2026 Highlights:
– Net income was $23.5 million, or $0.79 per diluted share, up 4.2% from the first quarter, driven by continued growth in net interest income and lower credit loss expense.

– Return on average assets and return on average equity during the second quarter were 1.20% and 11.09%, respectively.

– Deposits increased 2.3% to $7.0 billion from the prior quarter and noninterest-bearing demand deposits increased to 31% of total deposits, from 30% for the prior quarter.

– Net interest income increased 1.0% from the prior quarter, driven by the growth in commercial real estate and commercial and industrial lending. The increase was further supported by an improved funding mix, including lower-cost interest-bearing deposits and reduced borrowings.

– Net interest margin decreased two basis points to 3.36%, due primarily to normalization of FHLB dividend income, which elevated interest income in the prior quarter.

– Asset quality remained strong as nonperforming assets to total assets was 0.12%, an improvement of four basis points from the prior quarter, and nonperforming loans to total loans was 0.15%, also an improvement of four basis points from the prior quarter.

– Hanmi returned 58% of second-quarter net earnings to shareholders in the form of $8.3 million in dividends and $5.2 million in share repurchases; capital ratios remained healthy with tangible common equity to tangible assets at 10.03%.

(Press release, Hanmi, JUL 21, 2026, View Source [SID1234670768])

Condensed Interim Financial Report

On July 21, 2026 Novartis reported Second Quarter and Half Year 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Novartis, JUL 21, 2026, View Source [SID1234669426])

Vaxart to Participate in BTIG Biotechnology Conference 2026

On July 21, 2026 Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, reported that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BTIG Biotechnology Conference 2026
Date: Tuesday, July 28, 2026
Format: 1×1 Meetings
Location: Virtual

Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.

(Press release, Vaxart, JUL 21, 2026, View Source [SID1234669361])

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

On July 21, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET5 and multi-time point SPECT6 imaging for patient selection using a "theranostic" approach.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication highlights TLX591-Tx’s differentiated clinical profile, including an intensified dosing schedule, prolonged tumor retention and low exocrine (salivary) gland irradiation. The authors also concluded that in a heterogeneous population representative of a real-world setting, TLX591-Tx therapy in combination with standard of care (SOC) demonstrated a manageable and predictable safety profile, and indicative efficacy with a median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.

Nat Lenzo, MD, Nuclear Medicine Oncologist and Principal Investigator on the ProstACT SELECT study commented, "A key objective of ProstACT SELECT was to determine whether PSMA-PET imaging could reliably identify patients suitable for TLX591-Tx therapy, and the results clearly support this approach. The results provide compelling evidence that the PSMA-PET imaging agent and TLX591-Tx are targeting the same disease sites, supporting the ongoing ProstACT Global trial for mCRPC7, where there remains significant unmet need for additional treatment options."

David N. Cade, MD, Group Chief Medical Officer, Telix, said, "The publication of ProstACT SELECT data further strengthens the scientific foundation for Telix’s lead therapeutic candidate, TLX591-Tx. The peer-reviewed results support our patient-selection strategy and demonstrate a differentiated pharmacologic profile characterized by durable tumor targeting, hepatobiliary clearance, and a manageable safety profile. Telix is further evaluating TLX591-Tx in the international multi-center Phase 3 ProstACT Global study, where we aim to meaningfully improve outcomes for patients living with advanced prostate cancer."

The full paper is available at: View Source

About ProstACT SELECT

The purpose of the ProstACT SELECT trial was to evaluate the utility of 68Ga-PSMA-PET imaging (Illuccix) to select patients for TLX591-Tx rADC therapy. The primary objectives were to determine whole body biodistribution and organ radiation dosimetry and assess the safety and tolerability of TLX591-Tx in patients with advanced mCRPC. rPFS was a secondary study objective.

(Press release, Telix Pharmaceuticals, JUL 21, 2026, View Source [SID1234669360])

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

On July 21, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported that the company will deliver an oral presentation and present a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Drug Discovery and Development, or AACR (Free AACR Whitepaper) D3, Conference, taking place July 21–24, 2026 in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will highlight the broad and actionable capabilities of the AP3 platform to rapidly identify and advance promising compounds into clinical development, focusing on the discovery of ACR-2316, the company’s novel clinical-stage, selective WEE1/PKMYT1 inhibitor.

Data being presented illustrate how AP3 can uncover drug-induced resistance mechanisms, in this case WEE1 inhibition-induced activation of PKMYT1, resulting in phosphorylation of CDK1 on Thr14, a direct PKMYT1 phosphorylation site. Moreover, AP3 enabled the development of ACR-2316 based on optimal intracellular pathway effects, including sustained activation of CDK1, CDK2, but importantly and also of PLK1, to drive potent pro-apoptotic tumor cell death.

"We are excited to present at AACR (Free AACR Whitepaper) D3 and to highlight the actionable power of our AP3 platform to rapidly translate intracellular pathway biology into differentiated drug candidates," said Kristina Masson, Ph.D., co-founder and EVP at Acrivon, and president and CEO of the company’s research subsidiary, Acrivon AB, in Lund, Sweden. "Our presentations underscore how AP3 moves beyond traditional target-centric drug discovery by directly measuring drug-regulated pathway activity in intact cells, enabling optimal biology-based design of compounds for superior clinical activity and patient benefit. ACR-2316 is a compelling example of this strategy, and we look forward to sharing our findings at the conference."

ACR-2316 is currently in a Phase 1/2 clinical study advancing toward the dose expansion phase. Initial observations have shown tumor shrinkage, including PRs, and durable clinical benefit in subjects with small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), AP3-predicted tumor types not previously shown to be sensitive to other clinical WEE1 or PKMYT1 inhibitors. The compound has also demonstrated a favorable, differentiated tolerability profile observed in studies conducted to date, with adverse events primarily limited to only transient, mechanism-based neutropenia and a notable absence of non-hematological adverse events.

Presentations and Details

Oral Podium Presentation

Title: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug Discovery
Presenter: Lei Shi, Ph.D., Director and Head, AP3 Pathway Discovery, Acrivon Therapeutics
Session: Biotech Spotlight Session 1: Novel Therapeutics
Date and Time: Thursday, July 23, 2026, 3:50–4:00 p.m. ET
Location: Grand Ballroom

Poster Presentation

Title: AP3-guided biological SAR enables discovery of ACR-2316, a novel clinical-stage WEE1/PKMYT1 inhibitor designed for CDK1/2 and PLK1 pathway activation
Poster Number: A082
Session: Poster Session A
Date and Time: Wednesday, July 22, 2026, 6:15–8:45 p.m. ET
Location: Back Bay Ballroom

(Press release, Acrivon Therapeutics, JUL 21, 2026, View Source [SID1234669359])